SCHEMBL22040239

SCHEMBL22040239

C[C@@H](CCC(=O)c1ccncc1)NC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 4/20 0.43
AAK1 Q2M2I8 2/20 0.41
HRH2 P25021 3/20 0.41
HRH1 P35367 3/20 0.41
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
PLOD2 O00469 2/20 0.39
PLOD3 O60568 2/20 0.39
PLOD1 Q02809 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
HIF1A Q16665 1/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA7 P43166 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23878339 1.00 CYP17A1 (0.43) CYP17A1AAK1HRH2HRH1LMNA
SCHEMBL23878298 0.84 ALDH1A1 (0.48) AAK1HRH2HRH1LMNAPLOD2
SCHEMBL24366656 0.79 JAK3 (0.49) HRH2HRH1LMNAATMCTSS
SCHEMBL22040170 0.79 TRPA1 (0.47) AAK1HRH2HRH1LMNATSHR
SCHEMBL31149150 0.79 TRPA1 (0.47) AAK1HRH2HRH1LMNATSHR
SCHEMBL17207477 0.79 AAK1 (0.43) AAK1LMNATSHRALDH1A1HPGD
SCHEMBL22040808 0.78 TRPA1 (0.43) AAK1CYP2D6CA1CA2CA7
SCHEMBL23891602 0.77 CHRNA1 (0.46) AAK1HRH2HRH1LMNATSHR
SCHEMBL22039739 0.76 TRPA1 (0.42) AAK1LMNATSHRALDH1A1HPGD
SCHEMBL22039758 0.76 TRPA1 (0.42) AAK1LMNATSHRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3889138-B1 HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF HINOVA PHARMACEUTICALS INC (CN) 2024-11-20 EP disclosed
US-20220087996-A1 Histone acetylase p300 inhibitor and use thereof HINOVA PHARMACEUTICALS INC. (CN) 2022-03-24 US disclosed
EP-3889138-A1 HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF Hinova Pharmaceuticals Inc. (CN) 2021-10-06 EP disclosed
EP-3889138-A1 HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF Hinova Pharmaceuticals Inc. (CN) 2021-10-06 EP disclosed
WO-2020108500-A1 HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF 成都海创药业有限公司 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220087996-A1 Histone acetylase p300 inhibitor and use thereof EP300, HDAC1, HDAC11 CYP17A1 1999/4885AAK1 1201/4885HRH2 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.